CHDN heads into September with an eye-catching divergence: a fresh analyst initiation sets a bullish tone, while options positioning has swung to its most put-heavy level of the past year.
The options story is the week's sharpest signal. The put/call ratio has climbed to 7.69 — well above its 20-day average of 5.97 — after touching 9.23 on August 27, the highest reading of the past 52 weeks. That kind of sustained put dominance points to heavy demand for downside protection. The move is not a one-day spike: the PCR has been running north of 8 for most of the past week, only easing slightly into Tuesday's close. The 20-day z-score is 0.82, so it's above average but not yet at a statistical extreme — the ratio has been structurally elevated all month, which makes the context more important than the single-day reading.
Short interest, by contrast, tells a quieter story. Bears have been trimming. SI has fallen roughly 8.4% over the past month to 5.2% of the free float — down from over 4.1 million shares short in early August to around 3.6 million now. The lending market is loose: availability is running at 1,815%, meaning shares to borrow are plentiful relative to current short positions. Cost to borrow is a negligible 0.39%, down 24% over the past month. There is no meaningful squeeze setup here. The put-heavy options positioning and the retreating short interest are pulling in opposite directions — downside protection is being bought, but not via the short-selling route. That combination suggests hedging activity more than outright bearish conviction.
The Street remains constructive on the name despite a difficult few months for the stock. Wolfe Research initiated coverage Wednesday with an Outperform rating and a $119 target — a useful data point given the stock closed at $86.65, implying roughly 37% upside to that initiation price. The broader analyst consensus is Buy, with a mean price target of $130.58 across nine covering analysts. That gap between the current price and Street targets has been widening: Wells Fargo trimmed its target to $117 in late July after maintaining Overweight, and Citizens cut to $137 from $149 after the Q2 print, while Mizuho nudged its target up to $157. The direction of travel on targets has been mixed — some raising, some trimming — but nobody has pulled their positive rating. The bull case centres on 25% EBITDA growth in the Live and Historical Racing segment, driven by Kentucky and Virginia Historical Racing Machines. Bears point to flat Gaming segment EBITDA and weak price momentum.
Valuation has compressed alongside the stock's slide. The P/E has contracted by roughly 1x over the past week to 12.0x, and the EV/EBITDA multiple is running at 8.7x — both moving lower as the price drifts down from a month-ago high. The forward EPS momentum factor scores at the 100th percentile, the strongest component in the factor profile, while near-term EPS momentum (30-day) scores just 19 — a gap that reflects improving analyst forecasts running ahead of current price action. Peers had a rough week: PENN fell 7.6%, FLUT dropped nearly 5%, and MCRI shed 5% — CHDN's 2.3% weekly decline looks relatively contained against that backdrop.
Earnings are due October 28. The past two reports each produced an immediate negative reaction — the stock fell roughly 4.8% and 7.3% on the respective next days, with modest further weakness over the following week. With nine weeks to that print, the current put-heavy positioning may partly reflect early hedging into that known catalyst. The key variable to watch in the interim is whether the gap between the current price and the $119–$157 analyst target range begins to narrow — or whether further target cuts bring the Street closer to where the market is already trading.
See the live data behind this article on ORTEX.
Open CHDN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
